Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Mantle cell lymphoma

New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma

Ulas D. Bayraktar, MD

Melanoma

New Indication: Perioperative Pembrolizumab in Melanoma

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Neoadjuvant Nivolumab for NSCLC

Ulas D. Bayraktar, MD

Colorectal Cancer

New Indication: Avelumab for MSI-High Metastatic Colorectal Cancer

Ulas D. Bayraktar, MD

Follicular Lymphoma

New Reference: SubQ Rituximab for Follicular Lymphoma

Ulas D. Bayraktar, MD

Chronic Lymphocytic Leukemia

New Reference: Ibrutinib and Rituximab for CLL

Ulas D. Bayraktar, MD

Gastrointestinal Stromal Tumor

New Drug: Ripretinib for Advanced GIST

Ulas D. Bayraktar, MD

Bladder Cancer

New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer

Ulas D. Bayraktar, MD

Colorectal Cancer

New Protocl: Trifluridine-Tipiracil and Bevacizumab in Metastatic Colorectal Cancer

Ulas D. Bayraktar, MD

Mantle cell lymphoma

New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma

International, randomized, double-blind, phase 3 trial (SHINE) 65 years of age or older mantle cell lymphoma Untreated, stage II to IV disease Ibrutinib (N:261) or placebo (N:262),

New Indication: Perioperative Pembrolizumab in Melanoma

Open-label, phase 2 study Treatment naïve resectable sage IIIB-IVC metastatic melanoma (cutaneous, acral, or mucosal) Pembrolizumab: Neoadjuvant-adjuvant (n=154) vs. Adjuvant (n=1

Non-Small Cell Lung Cancer

New Indication: Neoadjuvant Nivolumab for NSCLC

Open-label, phase 3 trial Stage IB to IIIA resectable NSCLC Three cycles neoadjuvant treatment Nivolumab plus platinum-based chemotherapy (n=176) or platinum-based chemotherapy (n=

Colorectal Cancer

New Indication: Avelumab for MSI-High Metastatic Colorectal Cancer

A Phase II, Randomized, Open-label, multicenter trial Progression under first-line treatment (except for immunotherapy) of dMMR/MSI metastatic colorectal cancer Avelumab (n=65) vs

Follicular Lymphoma

New Reference: SubQ Rituximab for Follicular Lymphoma

Randomized, open-label phase 3 trial (LYSA) Previously untreated low-burden Follicular lymphoma SOC (n=102) vs. Rituximab sc (n=100)

Chronic Lymphocytic Leukemia

New Reference: Ibrutinib and Rituximab for CLL

Phase III, randomized,controlled, multicenter, open-label trial (FLAIR) Treatment naive CLL–small lymphocytic lymphoma (SLL) İbrutinib + Rituximab (n=386) vs. FCR (n=385)

Gastrointestinal Stromal Tumor

New Drug: Ripretinib for Advanced GIST

Randomized, open-label, international, multicenter phase III study Advanced GIST who progressed on or were intolerant to first-line treatment with imatinib Ripretinib 150 mg (n = 2

New Protocol: Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer

Multicenter, open-label, phase 1/2 trial Cisplatin ineligible local advanced/metastatic urothelial carcinoma Enfortumab vedotin +pembrolizumab q21 (n=45)

Colorectal Cancer

New Protocl: Trifluridine-Tipiracil and Bevacizumab in Metastatic Colorectal Cancer

Phase III, randomized, open-label trial (SUNLIGHT) Adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag